In its final days, the Biden administration's FDA is expected to propose a limit on the amount of nicotine in cigarettes.

Dr. Scott Manthei of the Nevada Ear and Sinus Institute has been advising patients against taking drugs like Sudafed for ...

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.

It’s taken nearly a decade for the U.S. FDA to go from zero to 60 in approving biosimilars. Currently, 63 biosimilars have been approved in the U.S., thanks to 18 new approvals in 2024 that stretched ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...

this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's," said Patrizia Cavazzoni, head of the FDA's Center for Drug Evaluation and Research ...

The approval of Aduhelm based on clearance of amyloid plaques in the brain as a surrogate marker – with an "expectation of clinical benefit" according to Patrizia Cavazzoni, director of the FDA ...

According to CDER Director Patrizia Cavazzoni, CDER’s new Center for Real-World Evidence Innovation represents a major step ...